These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 17172656)

  • 21. Theoretical mechanisms for synthesis of carcinogen-induced embryonic proteins: XIV. Mutational and non-mutational mechanisms as subsets of a more general mechanism. Part C. A defined cancer mutation.
    Hancock RL
    Med Hypotheses; 1985 Nov; 18(3):199-206. PubMed ID: 3853079
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncogenes on my mind: ERK and MTOR signaling in cognitive diseases.
    Krab LC; Goorden SM; Elgersma Y
    Trends Genet; 2008 Oct; 24(10):498-510. PubMed ID: 18774199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Networking with mitogen-activated protein kinases.
    Pelech SL; Charest DL; Mordret GP; Siow YL; Palaty C; Campbell D; Charlton L; Samiei M; Sanghera JS
    Mol Cell Biochem; 1993 Nov; 127-128():157-69. PubMed ID: 7935348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targets for signal-transducing protein kinases.
    Hunter T; Angel P; Boyle WJ; Chiu R; Freed E; Gould KL; Isacke CM; Karin M; Lindberg RA; van der Geer P
    Cold Spring Harb Symp Quant Biol; 1988; 53 Pt 1():131-42. PubMed ID: 3076078
    [No Abstract]   [Full Text] [Related]  

  • 25. Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?
    Felsher DW
    Cancer Res; 2008 May; 68(9):3081-6; discussion 3086. PubMed ID: 18451131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Signalling pathways as targets for anticancer drug development.
    Powis G
    Pharmacol Ther; 1994; 62(1-2):57-95. PubMed ID: 7991648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
    Workman P
    Expert Rev Anticancer Ther; 2002 Dec; 2(6):611-4. PubMed ID: 12503197
    [No Abstract]   [Full Text] [Related]  

  • 28. Two-component signal transduction as potential drug targets in pathogenic bacteria.
    Gotoh Y; Eguchi Y; Watanabe T; Okamoto S; Doi A; Utsumi R
    Curr Opin Microbiol; 2010 Apr; 13(2):232-9. PubMed ID: 20138000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and implementation of three mitogen-activated protein kinase (MAPK) signaling pathway imaging assays to provide MAPK module selectivity profiling for kinase inhibitors: MK2-EGFP translocation, c-Jun, and ERK activation.
    Nickischer D; Laethem C; Trask OJ; Williams RG; Kandasamy R; Johnston PA; Johnston PA
    Methods Enzymol; 2006; 414():389-418. PubMed ID: 17110204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Discovery and clinical application of mutations in the cancer genome].
    Mano H
    Nihon Rinsho; 2015 Aug; 73(8):1251-5. PubMed ID: 26281674
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guilty as charged: B-RAF is a human oncogene.
    Garnett MJ; Marais R
    Cancer Cell; 2004 Oct; 6(4):313-9. PubMed ID: 15488754
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathways: comparing the effects of drugs and T cells to effectively target oncogenes.
    Anders K; Blankenstein T
    Clin Cancer Res; 2013 Jan; 19(2):320-6. PubMed ID: 23197254
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oncogene products as therapeutic targets for cancer.
    Huang PS; Heimbrook DC
    Curr Opin Oncol; 1997 Jan; 9(1):94-100. PubMed ID: 9090500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mutation of the PIK3CA oncogene in human cancers.
    Karakas B; Bachman KE; Park BH
    Br J Cancer; 2006 Feb; 94(4):455-9. PubMed ID: 16449998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogene-blocking therapies: new insights from conditional mouse tumor models.
    Hengstler JG; Bockamp EO; Hermes M; Brulport M; Bauer A; Schormann W; Schiffer IB; Hausherr C; Eshkind L; Antunes C; Franzen A; Krishnamurthi K; Lausch E; Lessig R; Chakrabarti T; Prawitt D; Zabel B; Spangenberg C
    Curr Cancer Drug Targets; 2006 Nov; 6(7):603-12. PubMed ID: 17100566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted Cancer Therapy: Vital Oncogenes and a New Molecular Genetic Paradigm for Cancer Initiation Progression and Treatment.
    Willis RE
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Broad and thematic remodeling of the surfaceome and glycoproteome on isogenic cells transformed with driving proliferative oncogenes.
    Leung KK; Wilson GM; Kirkemo LL; Riley NM; Coon JJ; Wells JA
    Proc Natl Acad Sci U S A; 2020 Apr; 117(14):7764-7775. PubMed ID: 32205440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired Resistance Is Oncogene and Drug Agnostic.
    Doebele RC
    Cancer Cell; 2019 Oct; 36(4):347-349. PubMed ID: 31614114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transformation of mammalian cells by constitutively active MAP kinase kinase.
    Mansour SJ; Matten WT; Hermann AS; Candia JM; Rong S; Fukasawa K; Vande Woude GF; Ahn NG
    Science; 1994 Aug; 265(5174):966-70. PubMed ID: 8052857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting the mTOR signaling network in cancer.
    Chiang GG; Abraham RT
    Trends Mol Med; 2007 Oct; 13(10):433-42. PubMed ID: 17905659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.